|
Elucidation of cancer pathways and druggable targets using mouse models.
|
5U01CA084294-12
|
$729,463
|
$72,946
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$846,000
|
$126,900
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-14
|
$1,182,811
|
$804,311
|
Albelda, Steven
|
UNIVERSITY OF PENNSYLVANIA
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
1U01CA151452-01
|
$482,687
|
$482,687
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
THE THERAPY OF AML
|
5P01CA055164-18
|
$2,483,417
|
$322,844
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
2T32CA009515-26
|
$616,306
|
$616,306
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
MicroRNA therapeutics for prostate cancer
|
1R43CA137939-01A1
|
$282,967
|
$282,967
|
Bader, Andreas
|
MIRNA THERAPEUTICS, INC.
|
|
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB
|
2R01CA073756-11A1
|
$260,174
|
$260,174
|
BALDWIN, ALBERT
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
1P01CA132681-01A2
|
$3,043,786
|
$2,648,094
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Molecular Control of EGF Receptor Down-Regulation
|
5R01CA099163-10
|
$338,884
|
$111,832
|
Band, Hamid
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Malignant melanoma: Regulation by AP-2 and PAR-1
|
5R01CA076098-11
|
$271,063
|
$67,766
|
BARELI, MENASHE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
5K99CA139006-02
|
$115,239
|
$115,239
|
Bartholomeusz, Chandra
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Postdoctoral Research Training in Biotherapy of Cancer
|
5T32CA113263-05
|
$245,963
|
$49,193
|
BARTLETT, DAVID
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Imaging of gene expression in glioblastoma
|
5R01CA109620-05
|
$277,775
|
$277,775
|
Basilion, James
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
2P50CA083639-11
|
$2,231,452
|
$267,774
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
1R01CA142873-01
|
$320,588
|
$105,794
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Tumor-Targeting Oligonucleotides
|
5R01CA122383-05
|
$255,082
|
$63,771
|
BATES, PAULA
|
UNIVERSITY OF LOUISVILLE
|
|
Characteristics of Multidrug Resistance in Human Tumors
|
5R01CA040570-23
|
$261,339
|
$65,335
|
BECK, WILLIAM
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
BRAIN TUMOR SPORE GRANT
|
5P50CA097257-09
|
$2,252,870
|
$112,644
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Mechanism of p53 Silencing By Adenovirus E1B 55K Protein
|
5R01CA064799-14
|
$223,112
|
$223,112
|
BERK, ARNOLD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-12
|
$534,606
|
$106,921
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-32
|
$218,479
|
$43,696
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Image-guided Prodrug and siRNA Targeting of Cancer
|
5R01CA138515-02
|
$340,300
|
$340,300
|
Bhujwalla, Zaver
|
JOHNS HOPKINS UNIVERSITY
|
|
Re-activation of maspin tumor suppressor gene by designed transcription factors
|
5R01CA125273-04
|
$277,400
|
$69,350
|
BLANCAFORT, PILAR
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-09
|
$309,061
|
$30,906
|
Bland, Kirby
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Mechanisms of Viral Fusion and Inactivation
|
ZIA BC 008303
|
$399,730
|
$39,973
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Lipid-based Nanocapsules and Triggered Chemotherapy
|
ZIA BC 010652
|
$599,594
|
$179,878
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-07
|
$287,384
|
$71,846
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
1R01CA140655-01A1
|
$320,588
|
$105,794
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Tumor exosomes as agents of genetic change
|
5R01CA141150-02
|
$293,820
|
$293,820
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Regulation of the Sodium/Iodide Symporter in Breast
|
5R01CA089364-08
|
$215,460
|
$21,546
|
BRENT, GREGORY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-02
|
$393,420
|
$393,420
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Invasive Behavior of Tumor Cells Producing Collagenase-1
|
5R01CA077267-09
|
$243,034
|
$48,607
|
BRINCKERHOFF, CONSTANCE
|
DARTMOUTH COLLEGE
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
5R01CA095731-08
|
$274,814
|
$137,407
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Gene repression by HSF1 during hyperthermia and other stresses.
|
5R01CA077465-07
|
$227,020
|
$22,702
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer
|
1K08CA142904-01A1
|
$173,448
|
$173,448
|
Camp, Ernest
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
Cell Therapy of Refractory Leukemia
|
5R01CA113482-05
|
$289,553
|
$95,552
|
CAMPANA, DARIO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
1R01CA151391-01
|
$350,957
|
$175,479
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INSTITUTE
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-02
|
$682,666
|
$170,667
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
Aspects of MUC13 Mucin in Cancer
|
1R01CA142736-01A1
|
$329,906
|
$164,953
|
Chauhan, Subhash
|
SANFORD RESEARCH/USD
|
|
Combination gene therapy for metastatic colon cancer
|
5R01CA070337-14
|
$287,106
|
$287,106
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Overcoming Immune Suppression to Enhance Tumor Vaccine Efficacy
|
5R01CA090427-07
|
$326,284
|
$326,284
|
Chen, Si-Yi
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells
|
5R01CA109322-05
|
$262,923
|
$52,585
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Targeted delivery of IKKalpha siRNA to prostate cancer cells
|
1R21CA143683-01
|
$173,980
|
$173,980
|
Cheng, Kun
|
UNIVERSITY OF MISSOURI KANSAS CITY
|
|
VEGF and PDGF in angiogenesis and tumor progression
|
5R37CA050286-22
|
$476,313
|
$119,078
|
CHERESH, DAVID
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Ultrasound-guided gene delivery in pancreatic cancer
|
5R03CA140024-02
|
$71,000
|
$71,000
|
Claudio, Pier Paolo
|
MARSHALL UNIVERSITY
|
|
Ultrasound guided site-specific gene delivery in prostate cancer
|
5R21CA131395-02
|
$154,000
|
$154,000
|
Claudio, Pier Paolo
|
MARSHALL UNIVERSITY
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-04
|
$278,768
|
$278,768
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
MOTILITY AND INVASION
|
5P01CA100324-08
|
$2,091,643
|
$209,164
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Boosting anti-tumor immune responses by modulating genes with nanoparticles
|
5R21CA132026-02
|
$205,073
|
$205,073
|
Conejo-Garcia, Jose
|
DARTMOUTH COLLEGE
|
Total relevant funding to Gene Therapy for this search: $72,081,945
|